林秀芬：不断深挖海洋生物医药资源潜力

Core Viewpoint - The event focused on the theme of "Innovative Marine Biotechnology Empowering National Health," highlighting the advancements in marine medicine research and development by Xiamen Blue Bay Technology Co., Ltd. [1][4] Group 1: Company Overview - Blue Bay is a national high-tech enterprise specializing in the development of marine polysaccharide raw materials, formulations, health foods, and pharmaceuticals since its establishment in 2005 [4]. - The company has developed over 10 marine biological projects in collaboration with various universities and research institutions, with more than 20 invention patents pending [4]. Group 2: Product Development - Blue Bay's product matrix is centered around three main pillars: high-purity glucosamine sulfate, chitosan oligosaccharides, and selenium carrageenan [4]. - The company has achieved a production scale of 200 tons per year for glucosamine, with products set to launch in May 2024 and inclusion in the Fujian Province medical insurance directory as of September this year [4]. Group 3: Research Collaborations - Collaborations with academic institutions include partnerships with Professor Zhai Maolin's team at Peking University and Academician Tan Tianwei's team at Beijing University of Chemical Technology for the development of chitosan oligosaccharides, achieving a stable deacetylation degree of over 94% [4]. - The organic selenium technology, developed in collaboration with Professor Luo Dazhen's team at Peking University, is set for research completion in 2024 [5]. Group 4: Infrastructure and Future Plans - The establishment of the Blue Bay Bio-Manufacturing Center on October 27 marks a significant enhancement in the company's industrialization capabilities [5]. - Blue Bay has built a production base of over 40,000 square meters with 11 production lines, including two 100-ton polysaccharide raw material production lines, and aims to continue leveraging academic and research partnerships to explore marine biological resources [5].